Real-world patterns on tumor mutation burden testing in a pan-tumor population.

Autor:	Gautam S; ConcertAI, Memphis, TN 38119, USA., Kachroo S; Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ 07065, USA., DeClue RW; ConcertAI, Memphis, TN 38119, USA., Fisher MD; ConcertAI, Memphis, TN 38119, USA., Basu A; The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, The University of Washington, Seattle, WA 98195, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2021 May; Vol. 17 (15), pp. 1879-1887. Date of Electronic Publication: 2021 Jan 29.
DOI:	10.2217/fon-2020-1005
Abstrakt:	Background: There is limited real-world information on use of tumor mutational burden (TMB) testing and characteristics of patients receiving it. Materials & methods: Patients ≥18 years old and diagnosed with advanced solid tumors between 1 January 2015 and 31 January 2019 with TMB testing (TMB cohort) and without it (non-TMB) were included in this retrospective, observational study. Results: The TMB cohort (n = 202) was younger than non-TMB (n = 212) (mean age: 62.1 vs 65.6 at diagnosis; p = 0.005). There were more Black patients in the TMB cohort (21.3 vs 11.8% in non-TMB; p = 0.004). Clinical characteristics were comparable between the two cohorts; however, systemic anticancer treatment was higher among TMB cohort (91.6 vs 77.8% in non-TMB). Conclusion: Notable differences were observed between patients receiving TMB test and those not receiving it.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu